Speaker Profile
Ph.D., Vice President of Data Science, Strand Life Sciences
Biography
Badri Padhukasahasram leads data science strategy and execution at Strand Life Sciences, translating advances in AI and computational biology into pharma-facing solutions for drug discovery, precision medicine, and diagnostics. His portfolio spans single-cell and bulk transcriptomics foundation models, cellular perturbation modeling for drug response prediction, AI-driven early cancer detection, proteomics analytics, and therapeutic target prioritization using genome-wide association studies.
With over two decades of experience in computational biology and large-scale omics analysis, Badri specializes in population genomics, complex disease genetics, polygenic risk prediction, genome-wide association studies, pharmacogenomics, non-invasive prenatal testing, and oncology diagnostics. His expertise includes developing statistical methods, algorithms, theoretical frameworks, and simulation tools to extract biological insights from complex omics data. His industry experience includes roles at Illumina and Roche, where he contributed to regulated clinical diagnostics.
Talk
Omics-Specific AI Foundation Models advance Precision Medicine
From genome to cell to patient, Strand Life Sciences advances precision medicine through omics-specific AI foundation models. VEINS prioritizes noncoding variants; cellular perturbation models predict drug responses and identify therapeutic targets; CytoRx AI enables single-cell based target discovery; and cfDNA methylation and fragmentomics models support blood-based multi-cancer early detection and minimal residual disease (MRD) monitoring.
AI and Data Sciences Showcase:
Strand Life Sciences
Strand Life Sciences is a Bengaluru-based computational biology and AI company partnering with global pharmaceutical and diagnostics leaders to translate complex multi-omic data into actionable biological and clinical insights. Its specialized AI foundation models and advanced analytics span therapeutic target discovery, biomarker development, drug response prediction, and blood-based early cancer detection, advancing precision medicine from genomic discovery to clinical application.
Session Abstract – PMWC 2027 Silicon Valley
The PMWC 2027 AI Company Showcase will provide a 15-30 minute time slot for selected AI companies to present their latest technologies to an audience of leading investors, potential clients, and partners. We will hear from companies building technologies that expedite the pre-clinical and clinical drug discovery and development process, accelerate patient diagnosis and treatment, or develop scalable systems framework to make AI and deep/machine learning a reality.
Davos of Precision Medicine
PMWC 2027 Program
January 27–29, 2027 · Santa Clara Convention Center
Swipe speakers · Tap a card for sessions →
In a few words.
PMWC is indeed The Davos of Biotech
PMWC Hall of Impact
Previous Speakers Include
Nobel laureates, technology founders, regulators, CEOs and scientific pioneers who have taken the PMWC stage.
